Illaris, a treatment for vulva diseases with only 13 patients in Korea, will try again to enter the insurance benefit zone. According to related industries, Novartis Korea submitted an application for Ilaris' benefit in April and is under discussion. However, the registration process is still expected to be difficult. The drug has already undergone two pay procedures but has not achieved its purpose. Ilaris, licensed in Korea in 2015, is a treatment for hereditary recurrence syndrome, and detailed diseases are divided according to abnormal genes.

Specifically, Ilaris can be prescribed for ¡ãCAPS, TRAPS, HIDS/MKD, and FMF ¡ã Systemic JIA in Korea. Among them, CAPS is classified again as ¡ãFCAS/FCU ¡ãMWS¡